CDK4 and breast cancer: Stemming from this evidence, we recently reported that increased expression of RANK is associated with intrinsic and acquired resistance to CDK4/6i in preclinical HR+/HER2− BC models and that this resistance can be overcome or prevented by targeting the RANK pathway with RANKL inhibitors [136].